UNSPSC 51123905: Ubisindine

This classification denotes an antiarrhythmic agent with the molecular formula C20H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) FV251T245M, chemically known as 2-(2-(diethylamino)ethyl)-2,3-dihydro-3-phenyl-1h-isoindol-1-one but more generally known as ubisindine, which bears US NIH Compound Identifier 168473. European Medicines Agency schedules Ubisindine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11374MIG.

UNSPSC 51123905 Ubisindine (Commodity) covers pharmaceutical products, specifically medications used in emergency medical care and broader pharmaceutical supply programs. State and local governments solicit under this code for direct medication procurement to support fire rescue operations, emergency medical services, and broader pharmacy benefit programs serving state employees, retirees, and Medicaid beneficiaries. The work includes supplying advanced life support medications with firm pricing, expiration-date guarantees, and replacement protocols; participating in multi-state cooperative purchasing frameworks for generic and over-the-counter pharmaceuticals; and responding to state-level requests for information on direct-to-manufacturer prescription programs. Issuing bodies include city purchasing departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota MMCAP). Vendors must comply with Good Manufacturing Practices, FDA requirements, OSHA Hazard Communication Standards, Drug Supply Chain Security Act certification, and accessibility documentation standards such as WCAG 2.2 Level AA conformance.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted an IFB (Solicitation 26P00188) on April 24, 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000.00 and a response deadline of April 8, 2026; this opportunity included a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, issued an RFP (Solicitation S1070000015802) posted January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC to participating state and local government facilities including Oregon, with evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.